drugset
drugset / Trial / NCT00650338

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension

NCT00650338 ↗

Phase 2 Completed 165 enrolled Santen Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

To investigate the dose-response relationship of DE-104 ophthalmic solution in lowering intraocular pressure (IOP) in subjects with Primary Open-Angle Glaucoma or Ocular Hypertension

Timeline

Start
2008-03
Primary completion
2008-09
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject DE-104 Unknown — Topical
Comparator Latanoprost Small molecule 0.005 % Topical

Indications

ocular hypertension open-angle glaucoma